Logo-bi
Original Research COVID-19
Khalil Ansarin ORCID, Ramin Tolouian, Mohammadreza Ardalan* ORCID, Ali Taghizadieh, Mojtaba Varshochi, Soheil Teimouri, Tahere Vaezi, Hamed Valizadeh, Parviz Saleh, Saeid Safiri ORCID, Kenneth R. Chapman ORCID
Bioimpacts. 2020;10(4): 209-215. doi: 10.34172/bi.2020.27
PMCID: PMC7502909     PMID: 32983936     Scopus ID: 85092050012    
Based on a randomized clinical trial, bromhexine is proposed as a potential therapeutic option in COVID-19. A total of 78 patients with similar demographic and disease characteristics were treated with results showing a significant reduction in ICU admissions.


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge